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Summary
Cyst ic Fibrosis (CF) is the most frequent lethal inheri ted disease in the white
populat ion. In CF pat ients,  the pulmonary compl icat ions are responsible for
the major i ty of morbidi ty and vir tual ly al l  mortal i ty.  Li fe expectancy has im-
proved dramatical ly over the last decades due to a higher eff icacy of the an-
t ibiot ic treatment but also due to improved mucolyt ic therapy, airway physio-
therapy and improved nutr i t ional strategies including the use of pancreat ic
enzyme preparat ions. Cene therapy is a promising new therapeut ic strategy
but not yet avai lable and probably wi l l  not be for the major i ty of the adult  pa-
t ients in short  t ime.
The opt imizat ion of ant ibiot ic treatment has been subiect of  research in our
Cyst ic Fibrosis center for several  years. To date, there is no consensus what
strategy of ant ibiot ic therapy is to be preferred. The inhalat ion of ant ibiot ics
seems an interest ing opt ion to reach the microorganisms in the airways.
Limited eff icacy of the inhalat ion of ant ibiot ics and l imited knowledge of the
pharmacokinet ics after ínhalat ion orovided a rat ionale for a number of studies
described in this thesis.  Nebul izers are the only devices current ly used in CF to
inhale ant ibiot ics. A drawback of inhalat ion therapy with nebul izers i  the low
deposit ion eff ic iency of the drug in the airways. Furthermore, because i t  is
t ime consuming, pat ient compl iance is relat ively low. Reasons why a dry pow-
der inhaler,  being a more eff ic ient and convenient al ternat ive, was developed
and invest igated.
ln chapter / a general  introduct ion is given. The actual knowledge of ínhala-
t ion therapy is summarized and obiect ives of the studies are def ined.
Subsequent ly,  general  aspects oÍ inhalat ion therapy with nebul izers are dis-
cussed in Part 1 (chapters 2 and 3) of this thesis. ln chapter 2 the technical as-
pects of nebul izat ion therapy are descr ibed and two basic types of nebul iz-
ers, the jet  and the ul trasonic nebul izer are discussed. Furthermore, the two
main parameters to evaluate the performance of nebul izers are def ined: the
droplet s ize distr ibut ion of the aerosol and the drug output rate.
The choice of the type of nebul izer for nebul izat ion of a certain drug solu-
t ion should ini t ia l ly be based on laboratory evaluat ion. The major part  of  the
mass or volume distr ibut ion should preferably correspond with aerodynamic
part ic le diameters in the range of 1 to 5 micrometer.  The intended drug out-
put must be real ized within a reasonable nebul izat ion t ime ( less than 30 min).
The relation between in vítro and in vivo deposition is only partly understood
and to date it has not been possible to predict drug delivery Írom in vitro
studies on nebul izers only.  Therefore, pat ients '  studies hould be performed




Furhe rmore ,  t he  mechan i ca l  p rope r t i es  o f  nebu l i ze rs  a re  l i ke l y  t o  change  du r -
ing use.  Incorrect  c leaning,  maintenance and d is infect ion procedures may
change the nebul izer  per formance in t ime.  Reason why the per formance of  a
nebu l i ze r  shou ld  be  checked  pe r i od i ca l l y .
ln  chapter  3 c leaning and d is infect ion methods for  nebul izers are rev iewed.
Based on the ex is t ing methods the conclus ion is  drawn that  a general  c lean-
i ng  and  d i s i n fec t i on  me thod  fo r  a l l  common  nebu l i ze rs  i s  f eas ib le .
The studies described in Part 2 (chapters 4 to 7) of this thesis started with a
p rac t i ca l  ques t i on :  Wh lch  nebu l i ze r  shou ld  be  used  fo r  i nha la t i on  o f  t o -
bramycin and how should the apparatus be used in pract ice?
Fourteen commercia l ly  avai lable je t  and u l t rasonic nebul izers were invest i -
gated wi th the a im to select  the most  su i table type of  apparatus for  the in-
ha la t i on  o Í  a10o /o  t ob ramyc in  so lu t i on .
Two di f ferent  techniques for  measurement  of  par t ic le  s ize d is t r ibut ion were
evaluated:  laser  d i f f ract ion and cascade impactor  analys is .  To standardize the
measurements,  a specia l  adapter  was constructed to connect  the devices to
the laser  d i f f ract ion apparatus.  The f ina l  se lect ion of  the nebul izers was based
on  pa r t i c l e  s i ze  d i s t r i bu t i on ,  ou tpu t  and  s tab le  pe r fo rmance  du r i ng  nebu l i za -
t i on .
I t  was  conc luded  tha t  3  1e t  nebu l i ze r  compresso r  comb ina t i ons  (Po r ta -Neb
Sidestream, Porta-Neb Ventst ream and Par iboy Par i  LC+) have a reasonable
output  and an acceptable par t ic le  s ize d is t r ibut ion for  the adminis t rat ion of  a
. l  0o lo tobramycin solut ion.  The Sidestream is  less sui table for  the adminis t ra-
t ion of  ant ib iot ics because of  a h igher  loss of  drug to the envi ronment  dur ing
exhalat ion.  In  pract ice,  the Ventst ream and the Par i  LC+,  known as so cal led
"breath assis ted,  open vent  nebul izers" ,  resul ted to be the only nebul izers
sui table for  fur ther  invest igat ions wi th tobramycin.  The Ventst ream was used
in fur ther  exoer iments.
The pract ica l  quest ion evolved to fur ther  invest igat ions a iming to improve the
ant ib iot ic  inhalat ion therapy in  CF pat ients.  Tobramycin and other  aminogly-
cosides exhib i t  rapid,  concentrat ion dependent  bacter ia l  k i l l ing.  However,  a
layer  of  v isc id mucus and a lg inate- l ike s l ime l imi ts  the d i f fus ion oÍ  ant ib iot ics
in CF pat ients.  Therefore,  a h igh concentrat ion at  the s i te  of  in fect ions is  of
pa ramoun t  impor tance .
However,  i t  is  l ike ly  that  not  a l l  s i tes of  in fect ion are reached by current  in-
halat ion therapy wi th ant ib iot ics and in case of  exacerbat ions in t ravenous ad-
minis tered ant ib iot ics are added.  l f  e f fect ive serum concentrat ions could be
reached by inhalat ion therapy as wel l ,  th is  method of  adminis t rat ion may be
an a l ternat ive for  in t ravenous t reatment .
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Summary
ln chapter 5 the development of a highly concentrated tobramycin solution
for inhalat ion is descr ibed. Several  tobramycin solut ions, ranging from 5 to
30o/o (mlv), were compared after aerosolation with a Porta-Neb Ventstream
jet nebul izer combinat ion and a Medix Sonix 2000 ul trasonic nebul izer.  Laser
diffraction and cascade impactor analysis were used for the particle size char-
acter izat ion of the aerosol ized solut ions. The outout rate was determined in
volume and mass outout oer minute.
From the output rate measurements it was concluded that a 20o/o to-
bramycin solut ion is the opt imal and maximal concentrat ion to be
aerosol ized. The iet  nebul izer combinat ion was found to be the most sui table.
Using the jet  nebul izer combinat ion and the 20olo solut ion, i t  is possible to ad-
minister a dose of 1000 mg tobramycin by inhalat ion within 30 minutes.
Based on the ln vitro results, the nebulization of a high dose of tobramycin
aiming at a therapeut ic serum concentrat ion was further invest igated in CF
patients.
The aim of the pilot study described in chapter 6 was to assess the pharma-
cokinet ics of tobramycin under opt imal and standardized aerosol c ircum-
stances that were concluded Írom chapter 4. Six patients were studied after
inhalat ion of 600 mg tobramycin. A jet  nebul izer combinat ion loaded with a
1 0olo solut ion of tobramycin in water was used. The maximum serum levels of
tobramycin ranged Írom 0.77 mg/L to 3.63 mglL (mean 1.70 mg/L).  The
pharmacokinet ic data were best descr ibed by a two-compartment model.
Compared to intravenous administrat ion, a prolonged terminal hal f  l i fe was
found, which could be explained by the slow absorpt ion of tobramycin from
the si te of administrat ion ( f l ip-Í lop model).
Despite standardized aerosol condit ions, considerable interpat ient var iabi l -
ity was observed. However, the relatively low serum levels allow a further in-
crease of the dose.
ln chapter 5 i twas found that '1000 mg tobramycin (as a20o/o solut ion) is the
highest dose that can be nebul ized with current ly avai lable devices within a
reasonable t ime.
In the study described in chapter Z the pharmacokinet ics of tobramycin af-
ter inhalat ion of 1000 mg (as a 20o/o solut ion) with a Porta-Neb Ventstream
jet nebul izer combinat ion were invest igated in f ive pat ients.  The maximum
serum concentrat ions ranged from 1.78 to 3.25 mglL (mean 2.42 mglL).
Again a prolonged terminal hal f- l i fe was observed. The observed prolonged
residence t ime of tobramycin in the lung after inhalat ion oÍ a high dosage is
favorable regarding i ts cl in ical  ef fect.
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Summary
To date,  the exact  a i rway deposi t ion pat tern af ter  inhalat ion is  not  known.
Due to obstruct ions by mucus not  a l l  s i tes of  in fect ion wi l l  be reached.
Inha led  an t i b i o t i cs  mos t  l i ke l y  w i l l  r each  we l l  ven t i l a ted  segmen ts  o f  t he  a i r -
ways whereas systemical ly  adminis tered ant ib iot ics may reach the wel l  per-
fused regions.  Therefore,  in  t reatment  oÍ  exacerbat ions suf f ic ient ly  h igh
serum concentrat ions are a lso requi red.  l t  is  assumed that  peak serum levels
of  at  least  8 mg/L are requi red for  c l in ica l  ef f icacy.  Such concentrat ions can-
no t  be  reached  w i th  cu r ren t  i nha la t i on  t he rapy  on l y .  A Í t e r  i nha la t i on  o f  1000
mg a  tob ramyc in  peak  concen t ra t i on  o f  3 .25  mg /L  was  found  a t  max imum.
The deposi t ion and consequent ly  the concentrat ion of  tobramycin in  the a i r -
ways is  important  as the serum level  is  only  an indi rect  parameter  for  the ef f i -
cacy  o Í  t he  i nha la t i on  t he rapy .  The  h ighe r  admin i s te red  ose  gave  a  s i gn i f i -
cant  increase of  the area under the curve (AUC) ref lect ing the h igher  deposi -
t ion of  tobramycin in  the a i rways.  To evaluate the consequence of  the h igher
depos i t i on ,  a  pha rmacok ine t i c  i nha la t i on  mode l  was  cons t ruc ted  as  a  f i r s t
s tep to e luc idate the concentrat ion- t ime prof i le  of  tobramycin in  the a i rway
compar tmen t  and  the  resu l t i ng  se rum concen t ra t i on .  H igh  tob ramyc in  con -
centrat ions (> 100 mg/L)  were calculated for  the a i rway compartment .  A
high concentrat ion of  tobramycin in  the target  area is  cr i t ica l  for  the success
of  the therapy.  The s imulated tobramycin concentrat ions of  the a i rway com-
pa r tmen t  we re  we l l  above  m in ima l  i nh ib i t i on  concen t ra t i on  (M lC)  l eve l s  o Í
Pseudomonas aeruginosa.  These concentrat ion data are in  accordance wi th
measured sputum levels af ter  inhalat ion of  tobramycin or  gentamic in as re-
po r ted  i n  seve ra l  sLud ies .
The  i nha la t i on  mode l  may  a l so  be  used  to  answer  t he  ques t i on  whe the r  exac -
erbat ions can be t reated wi th inhaled tobramycin.  Using the Porta-Neb
Ven ts t ream comb ina t i on  an  i nha la t i on  t ime  o f  a t  l eas t  1  . 5  hou r  i s  necessa ry  t o
del iver  200 mg in the target  area,  which wi l l  lead to therapeut ic  serum con-
cen t ra t i ons .  Such  l ong  i nha la t i on  t imes  a re  no t  accep tab le  f o r  c l i n i ca l  t r ea t -
men I .
F inal ly ,  the model  of fers a Bayesian pr ior  in  therapeut ic  drug moni tor ing to
predict  accumulat ion of  serum levels and prevent  tox ic i ty .  Toxic  tobramycin
t rough levels are not  expected wi th a lungdose oÍ  44 or  67 mg twice a day,
which can be at ta ined wi th a nebul izer  dose of  600 and ' l  000 mg,  respec-
tively.
Nex t  t o  t ob ramyc in ,  co l i s t i n  i s  ano the r  an t i pseudomona l  d rug  used  by  i nha la -
t i on  i n  CF  pa t i en t s .  I n  Pa r t  3  o f  t h i s  t hes i s  s tud ies  w i t h  co l i s t i n  a re  desc r i bed .
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-Summary
To date, no pharmacokinet ic data or serum levels are avai lable after inhalat ion
of col ist in.  Pharmacokinet ic data of col ist in are l imited to intravenous admin-
istrat ion. These data are mainly based on microbiological  ssay techniques. In
case of inhalat ion therapy lower serum levels are to be expected. Therefore, a
sensit ive analyt ical  method with an acceptable coeff ic ient of  var iat ion is
needed for the determinat ion of col ist in in pat ient samples after inhalat ion.
The development and val idat ion of the method are descr ibedin chapter 8.
Nebul izat ion of a drug solut ion has some drawbacks, e.g. the long inhalat ion
t ime, the low pulmonary deposit ion, and the therapeut ic eff icacy. To improve
pat ient compl iance, a dry powder inhaler (DPl) provides a possible al ternat ive
for the nebul izat ion of aqueous olut ions of ant ibiot ics. Both the powder for-
mulat ion and the inhaler device contr ibute to i ts performance.
ln chapter 9 we describe the development of a col ist in dry powder dosage
form for inhalat ion. Furthermore, a new inhaler device, which operates ade-
quately at a wide range of inspiratory f lows, was constructed.
I t  is possible to increase the lung deposit ion of col ist in inhalat ion from 1O%o
to about 4oo/o Í  the inhaler device nominal dose. Furthermore, by using a
dry powder inhaler instead of a nebul izer the pat ient comfort  is increased by
the reduced t ime needed to administer the dose.
The test inhaler can be loaded with doses of 12 mg. Assuming a deposit ion
eff ic iency of 40o/o, approximately 5 mg col ist in wi l l  reach the airways. From
li terature data, the mean bioavai labi l i ty of a nebul izer is assumed to be ap-
proximately 10o/o Í  the nebul izer dose. To date, an aqueous olut ion of 160
mg of col ist in is used in maintenance therapy and approximately 16 mg wi l l
be deposited in the airways. This means that 3 inhalat ions of the powder for-
mulat ion are required in order to mimic the deposit ion of the nebul izat ion of
160 mg co l i s t in  as  a  so lu t ion .
We concluded that the new formulat ion in combinat ion with the test inhaler
may contr ibute to the eff icacy of the ant ibiot ic therapy in CF pat ients.  l t  is
very l ikely that the pat ient compl iance wi l l  benef i t  Í rom the increase in com-
fort .  These assumptions were invest igated in a cl in ical  study described in
chapter 1 0.
The aim of the study described in chapter 7 0 was to assess the feasibi l i ty of  the
new formulat ion in combinat ion with a new inhaler device in healthy volun-
teers. Furthermore, the feasibi l i ty of  the dry powder inhaler as compared to
the nebul izat ion of col ist in was invest igated in CF pat ients.  The test inhaler
used in chapter 9 was improved with a dose system. The serum concentra-
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t ions  o f  co l i s t in  a f te r  the  inha la t ion  o f  a  nebu l ized  so lu t ion  and a f te r  inha la -
t ion of a dry powder were used as an indirect parameter to compare the de-
posit ion eff ic iency of both inhalat ion systems in pat ients.
Volunteers and pat ients were asked to inhale a dose of 25 mg col ist in as a
dry powder mixture with lactose (col ist in content 83.3o/o).  The pat ients were
a lso  asked to  nebu l ize  160 mg co l i s t in  as  a  so lu t ion .
The individual pulmonary funct ion parameters (FEV1 and IVC scores) were
not signi f icant ly di f ferent before and after inhalat ion of the dry powder by the
volunteers nor after nebul izat ion of the solut ion by the pat ients.  In some CF
patients a decrease in pulmonary funct ion and cough was observed after in-
halat ion of the dry powder. The pulmonary funct ion recovered slowly.
ln pat ients the peak serum concentrat ions ranged from I8ïo 64 prg/L after in-
halat ion of 1 60 mg col ist in as a solut ion and f  rom 7 7 Io 1 59 prglL after in hala-
t ion of 25 mg col ist in as dry powder. Furthermore, the AUC tends to be
higher after inhalat ion oÍ the dry powder, indicat ing an even better deposi-
t ion for the dry powder inhaler than expected.
The new DPI Íormulat ion provides a potent ial  ef fect ive al ternat ive Íor neb-
u l i zed  co l i s t in .  The conven ience o f the  dev ice  is  a  ma jor  advantage and the
dosage form was highly appreciated by the pat ients.  l t  wi l l  improve pat ient
compl iance and may al low for a higher dosing frequency. The observed de-
c rease in  pu lmonary  func t ion  and cough in  some pat ien ts  a re  a  ser ious  draw-
back and are not acceptable for long term use. However,  there are several
possibi l i t ies to opt imize the dry powder inhaler.
This study shows that the dose of 25 mg col ist in can be drast ical ly reduced.
A dose of 10 mg col ist in sul fate wi l l  suff ice to mimic exposure of the current ly
used nebul izal ion oÍ 160 mg. The powder formulat ion can be further im-
proved by opt imizing the part ic le size distr ibut ion of the drug. This may lead
to greater accuracy of deposit ion in specif ic regions of the airways. Final ly,  a
lower dose in combinat ion with a bronchodi lator pretreatment may over-
come the observed side effects.  These improvement strategies are interest ing
sub jects for future studies.
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